Lymphoma Knowledge Hub

HIV Status Does Not Impact First-Line Treatment Outcomes in Patients with Hodgkin Lymphoma

A study presented at the 2020 Society of Hematologic Oncology Annual Meeting observed that among patients with advanced classical Hodgkin lymphoma (HL), both those...

Biologic Treatment for Rheumatoid Arthritis Not Linked to Lymphoma Risk

A study published in Rheumatology found that treatment with biologic disease-modifying anti-rheumatic drugs (DMARDs), including tumor necrosis factor inhibitors (TNFis) and non-TNFi biologic DMARDs,...

Lymphoma Survivors Need More Information on Late Effects, Screening Recommendations

A study published in the Journal of Cancer Survivorship found that adolescent and young adult lymphoma survivors may not be appropriately informed by their...

Anti-CD30 CAR T-Cell Therapy Associated with Durable Response in Patients with Lymphoma

A study published in the Journal of Clinical Oncology observed that anti-CD30 chimeric antigen receptor (CAR) T-cell therapy resulted in a durable response and...

Alternative Treatment for Anti-CD20 Immunotherapy Hypersensitivity Reaction in Patients with Lymphoma

For patients with lymphoma who experience severe drug hypersensitivity reactions related to anti-CD20 immunotherapy, use of an alternative anti-CD20 antibody is a safe alternative...

Decreased Quality of Life in Patients with Relapsed/Refractory DLBCL

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who receive standard of care therapy report decreased health-related quality of life and health utility, according...
pathogen micro organism background, 3d illustration

Optimal Timing of Methotrexate as CNS Prophylaxis in Patients with DLBCL

High-dose methotrexate is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk of central nervous system...

Journal Reading List

Advertisement
Advertisement
click me